Literature DB >> 24099710

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Joel C Sunshine1,2, Karlo Perica1,3,4, Jonathan P Schneck3,4,5,6, Jordan J Green1,2,5,7.   

Abstract

Previous work developing particle-based acellular, artificial antigen presenting cells (aAPCs) has focused exclusively on spherical platforms. To explore the role of shape, we generated ellipsoidal PLGA microparticles with varying aspect ratios (ARs) and synthesized aAPCs from them. The ellipsoidal biomimetic aAPCs with high-AR showed significantly enhanced in vitro and in vivo activity above spherical aAPCs with particle volume and antigen content held constant. Confocal imaging indicates that CD8+ T cells preferentially migrate to and are activated by interaction with the long axis of the aAPC. Importantly, enhanced activity of high-AR aAPCs was seen in a mouse melanoma model, with high-AR aAPCs improving melanoma survival compared to non-cognate aAPCs (p = 0.004) and cognate spherical aAPCs (p = 0.05). These findings indicate that particle geometry is a critical design criterion in the generation of aAPCs, and may offer insight into the essential role of geometry in the interaction between CD8+ T cells and biological APCs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Artificial antigen presenting cells; Biomimetic; Ellipsoidal; Immunotherapy; Microparticles; Particle shape

Mesh:

Year:  2013        PMID: 24099710      PMCID: PMC3902087          DOI: 10.1016/j.biomaterials.2013.09.050

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  41 in total

1.  The immunological synapse: a molecular machine controlling T cell activation.

Authors:  A Grakoui; S K Bromley; C Sumen; M M Davis; A S Shaw; P M Allen; M L Dustin
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

2.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Authors:  Mathias Oelke; Marcela V Maus; Dominic Didiano; Carl H June; Andreas Mackensen; Jonathan P Schneck
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

Review 3.  Location is everything: lipid rafts and immune cell signaling.

Authors:  Michelle Dykstra; Anu Cherukuri; Hae Won Sohn; Shiang-Jong Tzeng; Susan K Pierce
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 4.  Cell mechanics and the cytoskeleton.

Authors:  Daniel A Fletcher; R Dyche Mullins
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

Review 5.  Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers.

Authors:  Julie A Champion; Yogesh K Katare; Samir Mitragotri
Journal:  J Control Release       Date:  2007-04-11       Impact factor: 9.776

6.  Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells.

Authors:  Charles J Kroger; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

7.  T cell receptor signaling precedes immunological synapse formation.

Authors:  Kyeong-Hee Lee; Amy D Holdorf; Michael L Dustin; Andrew C Chan; Paul M Allen; Andrey S Shaw
Journal:  Science       Date:  2002-02-22       Impact factor: 47.728

8.  A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells.

Authors:  Erin R Steenblock; Tarek M Fahmy
Journal:  Mol Ther       Date:  2008-03-04       Impact factor: 11.454

9.  Why degradable polymers undergo surface erosion or bulk erosion.

Authors:  Friederike von Burkersroda; Luise Schedl; Achim Göpferich
Journal:  Biomaterials       Date:  2002-11       Impact factor: 12.479

Review 10.  Particle shape effects in vitro and in vivo.

Authors:  Bradley J Harris; Paul Dalhaimer
Journal:  Front Biosci (Schol Ed)       Date:  2012-06-01
View more
  84 in total

1.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

Review 2.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 3.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

4.  An automated multidimensional thin film stretching device for the generation of anisotropic polymeric micro- and nanoparticles.

Authors:  Randall A Meyer; Randall S Meyer; Jordan J Green
Journal:  J Biomed Mater Res A       Date:  2015-02-24       Impact factor: 4.396

Review 5.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

Review 6.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

7.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

Review 8.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

9.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

Review 10.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.